Labocanna Past Earnings Performance
Past criteria checks 0/6
Labocanna's earnings have been declining at an average annual rate of -8.3%, while the Pharmaceuticals industry saw earnings growing at 9.7% annually. Revenues have been declining at an average rate of 38.9% per year.
Key information
-8.3%
Earnings growth rate
28.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 29.4% |
| Revenue growth rate | -38.9% |
| Return on equity | -8.5% |
| Net Margin | -3,624.6% |
| Next Earnings Update | 10 May 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Labocanna makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -1 | 1 | 0 |
| 30 Sep 23 | -1 | -2 | 1 | 0 |
| 30 Jun 23 | -1 | -1 | 0 | 0 |
| 31 Mar 23 | 1 | 0 | 1 | 0 |
| 31 Dec 22 | 0 | -1 | 0 | 0 |
| 30 Sep 22 | 1 | -1 | 0 | 0 |
| 30 Jun 22 | 1 | -1 | 1 | 0 |
| 31 Mar 22 | 1 | -1 | 1 | 0 |
| 31 Dec 21 | 0 | -1 | 0 | 0 |
| 30 Sep 21 | 0 | 0 | 0 | 0 |
| 30 Jun 21 | 0 | 0 | 0 | 0 |
| 31 Mar 21 | 0 | 0 | 0 | 0 |
| 31 Dec 20 | 0 | 0 | 0 | 0 |
| 30 Sep 20 | 0 | 0 | 0 | 0 |
| 30 Jun 20 | 0 | 0 | 0 | 0 |
| 31 Mar 20 | 0 | 0 | 0 | 0 |
| 31 Dec 19 | 0 | 0 | 0 | 0 |
| 30 Sep 19 | 0 | -1 | 1 | 0 |
| 30 Jun 19 | 1 | -1 | 2 | 0 |
| 31 Mar 19 | 1 | -1 | 3 | 0 |
| 31 Dec 18 | 2 | -1 | 3 | 0 |
| 30 Sep 18 | 3 | -1 | 4 | 0 |
| 30 Jun 18 | 3 | -1 | 3 | 0 |
| 31 Mar 18 | 4 | -1 | 4 | 0 |
| 31 Dec 17 | 4 | -1 | 5 | 0 |
| 30 Sep 17 | 5 | -1 | 5 | 0 |
| 30 Jun 17 | 5 | -1 | 5 | 0 |
| 31 Mar 17 | 6 | -1 | 5 | 0 |
| 31 Dec 16 | 6 | -1 | 6 | 0 |
| 30 Sep 16 | 5 | 0 | 5 | 0 |
| 30 Jun 16 | 5 | 0 | 4 | 0 |
| 31 Mar 16 | 5 | 0 | 5 | 0 |
| 31 Dec 15 | 6 | 0 | 6 | 0 |
| 30 Sep 15 | 6 | 0 | 6 | 0 |
| 30 Jun 15 | 7 | 0 | 7 | 0 |
| 31 Mar 15 | 7 | 1 | 6 | 0 |
| 31 Dec 14 | 6 | 1 | 5 | 0 |
| 30 Sep 14 | 6 | 1 | 5 | 0 |
| 30 Jun 14 | 6 | 1 | 5 | 0 |
| 31 Mar 14 | 7 | 1 | 5 | 0 |
| 31 Dec 13 | 7 | 0 | 6 | 0 |
| 30 Sep 13 | 8 | 0 | 7 | 0 |
| 30 Jun 13 | 8 | 0 | 11 | 0 |
Quality Earnings: LCN is currently unprofitable.
Growing Profit Margin: LCN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LCN is unprofitable, and losses have increased over the past 5 years at a rate of 8.3% per year.
Accelerating Growth: Unable to compare LCN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LCN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (3%).
Return on Equity
High ROE: LCN has a negative Return on Equity (-8.54%), as it is currently unprofitable.